Ignyta, Inc.
(NASDAQ : RXDX)

( )
RXDX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.79%79.141.2%$541.48m
AMGNAmgen Inc.
-0.28%185.991.2%$522.30m
GILDGilead Sciences, Inc.
0.08%71.520.9%$518.25m
BIIBBiogen Inc.
0.16%297.341.2%$439.96m
NKTRNektar Therapeutics
-3.97%55.865.6%$383.38m
SRPTSarepta Therapeutics, Inc.
-2.63%149.6516.6%$325.83m
VRTXVertex Pharmaceuticals Incorporated
-0.67%156.571.9%$253.87m
REGNRegeneron Pharmaceuticals, Inc.
-2.34%329.042.6%$243.76m
ILMNIllumina, Inc.
-0.56%286.053.5%$191.71m
AAgilent Technologies, Inc.
0.40%63.041.5%$180.09m
BLUEBluebird Bio, Inc.
2.32%187.3515.7%$156.91m
ALXNAlexion Pharmaceuticals, Inc.
1.04%125.812.0%$149.34m
EXASExact Sciences Corporation
-0.74%68.8225.5%$144.87m
BMRNBioMarin Pharmaceutical Inc.
0.09%98.434.4%$139.42m
INCYIncyte Corporation
-1.28%72.492.5%$126.38m

Company Profile

Ignyta, Inc. is a precision oncology biotechnology company that engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. It plans focus on two product candidates: entrectinib, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors ROS1 and ALK proteins, which is in two Phase I/II clinical studies in molecularly defined patient populations for the treatment of solid tumors; and RXDX-103, a development program targeting the cell division cycle 7-related, or CDC7, protein kinase. The company was founded by Jonathan E. Lim on October 31, 2013 and is headquartered in San Diego, CA.